Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept.
Publication
, Journal Article
Mor, A; Bingham, CO; Barisoni, L; Lydon, E; Belmont, HM
Published in: J Rheumatol
April 2005
Tumor necrosis factor-alpha (TNF-alpha) is a proinflammatory cytokine. Agents that neutralize TNF-alpha are effective in the treatment of disorders such as rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), spondyloarthropathies, and inflammatory bowel disease. TNF-alpha antagonist therapy has been associated with the development of antinuclear antibodies (ANA) and double-stranded DNA (dsDNA) antibodies, as well as the infrequent development of systemic lupus erythematosus (SLE)-like disease. We describe the first case of biopsy-confirmed proliferative lupus nephritis and leukocytoclastic vasculitis in a patient treated with etanercept for JRA.
Duke Scholars
Published In
J Rheumatol
ISSN
0315-162X
Publication Date
April 2005
Volume
32
Issue
4
Start / End Page
740 / 743
Location
Canada
Related Subject Headings
- Withholding Treatment
- Vasculitis, Leukocytoclastic, Cutaneous
- Recombinant Fusion Proteins
- Receptors, Tumor Necrosis Factor
- Lupus Nephritis
- Immunoglobulin G
- Immunocompromised Host
- Humans
- Female
- Etanercept
Citation
APA
Chicago
ICMJE
MLA
NLM
Mor, A., Bingham, C. O., Barisoni, L., Lydon, E., & Belmont, H. M. (2005). Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. J Rheumatol, 32(4), 740–743.
Published In
J Rheumatol
ISSN
0315-162X
Publication Date
April 2005
Volume
32
Issue
4
Start / End Page
740 / 743
Location
Canada
Related Subject Headings
- Withholding Treatment
- Vasculitis, Leukocytoclastic, Cutaneous
- Recombinant Fusion Proteins
- Receptors, Tumor Necrosis Factor
- Lupus Nephritis
- Immunoglobulin G
- Immunocompromised Host
- Humans
- Female
- Etanercept